Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $100

Benzinga · 10/14 13:59
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $90 to $100.